Home

Coherus BioSciences, Inc. - Common Stock (CHRS)

0.9073
+0.0198 (2.23%)

Coherus Bio is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic solutions in the field of immunology and oncology

The company specializes in creating high-quality biologics, including biosimilars—products that are similar to already approved biological medicines. With a commitment to advancing patient care, Coherus Bio engages in research and clinical development to address unmet medical needs, aiming to make healthcare more accessible and affordable through its cutting-edge therapies.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close0.8875
Open0.9000
Bid0.9000
Ask0.9462
Day's Range0.8890 - 0.9500
52 Week Range0.6603 - 2.640
Volume1,607,425
Market Cap104.53M
PE Ratio (TTM)3.945
EPS (TTM)0.2
Dividend & YieldN/A (N/A)
1 Month Average Volume1,796,088

News & Press Releases

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
– Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures –– UDENYCA® net revenue increased 62% year-over-year –– LOQTORZI® net revenue increased 29% quarter-over-quarter –
By Coherus BioSciences, Inc. · Via GlobeNewswire · March 10, 2025
Earnings Scheduled For March 10, 2025benzinga.com
Via Benzinga · March 10, 2025
Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025
REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2024 financial results will be released after market close on Monday, March 10, 2025. Starting at 5:00 p.m. ET on March 10, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
By Coherus BioSciences, Inc. · Via GlobeNewswire · March 3, 2025
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference
REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in a fireside chat presentation at the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025, at 11:50 a.m., Eastern time. A live audio webcast will be accessible through a link posted on the “Events and Presentations” section of the Coherus’ investor website: https://investors.coherus.com/events-presentations. A replay of the presentation will be available on this same website for approximately 90 days.
By Coherus BioSciences, Inc. · Via GlobeNewswire · February 24, 2025
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
– Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate –
By Coherus BioSciences, Inc. · Via GlobeNewswire · January 22, 2025
Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 5:15 p.m. Pacific Time. The presentation and Q&A session will be accessible via Webcast through a link posted on the Investor Events Calendar section of the Coherus website: https://investors.coherus.com/events-presentations. This webcast will be available for replay until February 10, 2025.
By Coherus BioSciences, Inc. · Via GlobeNewswire · January 8, 2025
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer -
By Coherus BioSciences, Inc. · Via GlobeNewswire · December 18, 2024
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · December 3, 2024
Why Is Coherus BioSciences Stock Trading Higher On Tuesday?benzinga.com
Coherus sells Udenyca franchise for up to $558.4 million, shifts focus to immuno-oncology R&D, and plans clinical trials in hepatocellular carcinoma and NSCLC.
Via Benzinga · December 3, 2024
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
- Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI®, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor -
By Coherus BioSciences, Inc. · Via GlobeNewswire · December 3, 2024
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in the 2024 Citi Global Healthcare Conference, with Dr. Theresa LaVallee, Chief Development Officer, sitting on the Novel Mechanisms in Oncology Panel on December 3, 2024, at 3:15 p.m. ET.
By Coherus BioSciences, Inc. · Via GlobeNewswire · November 27, 2024
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga.com
Via Benzinga · November 7, 2024
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
– Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA® net revenue, quarter-over-quarter –
By Coherus BioSciences, Inc. · Via GlobeNewswire · November 6, 2024
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its third quarter 2024 financial results will be released after market close on Wednesday, November 6, 2024. Starting at 5:00 p.m. ET on November 6, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
By Coherus BioSciences, Inc. · Via GlobeNewswire · October 30, 2024
CHRS Stock Earnings: Coherus BioSciences Beats EPS, Beats Revenue for Q2 2024investorplace.com
CHRS stock results show that Coherus BioSciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 8, 2024
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
– Net revenue of $65.0 million in Q2 2024 –
By Coherus BioSciences, Inc. · Via GlobeNewswire · August 8, 2024
Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024
REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its second quarter 2024 financial results will be released after market close on Thursday, August 8, 2024. Starting at 5:00 p.m. EDT on August 8, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
By Coherus BioSciences, Inc. · Via GlobeNewswire · August 1, 2024
Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiarytalkmarkets.com
Shanghai Henlius Biotech agreed to be a wholly owned subsidiary of Fosun in a $690 million deal that values the company at $1.7 billion. Meanwhile, Suzhou Ascentage Pharma filed to list in the US to support its portfolio of drugs.
Via Talk Markets · June 30, 2024
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
– Transaction aligns with Coherus’ strategic focus on oncology –
By Coherus BioSciences, Inc. · Via GlobeNewswire · June 27, 2024
Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
Former Global Controller of Merck & Co., Inc. Enhances Financial, Operational and Strategic Transformational Expertise
By Coherus BioSciences, Inc. · Via GlobeNewswire · June 5, 2024
Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the 2024 Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 8:30 a.m. Eastern Daylight Time / 5:30 a.m. Pacific Daylight Time. The presentation will be accessible via Webcast through a link on the Investor Events and Presentations section of the Coherus website: https://investors.coherus.com/events-presentations. This webcast will be available for replay until July 7, 2024.
By Coherus BioSciences, Inc. · Via GlobeNewswire · May 30, 2024
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors
By Coherus BioSciences, Inc. · Via GlobeNewswire · May 23, 2024
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the upcoming TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA on Wednesday, May 29, 2024 at 12:00 p.m. Eastern Daylight Time / 9:00 a.m. Pacific Daylight Time. The presentation will be accessible via Webcast through a link on the Investor Events and Presentations section of the Coherus website: https://investors.coherus.com/events-presentations. This webcast will be available for replay until June 26, 2024.
By Coherus BioSciences, Inc. · Via GlobeNewswire · May 23, 2024
CHRS Stock Earnings: Coherus BioSciences Misses EPS, Misses Revenue for Q1 2024investorplace.com
CHRS stock results show that Coherus BioSciences missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 9, 2024
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
 – Net revenue of $77.1 million in Q1 2024 – 
By Coherus BioSciences, Inc. · Via GlobeNewswire · May 9, 2024